MyFinsight
Home
Blog
About
Contact
Download
Download image
Proceeds from maturity of
short-term investments
$864,273K
Proceeds from issuance of
common stock upon...
$1,093K
Proceeds from issuance of
common stock upon stock...
$126K
Proceeds from sale of
short-term investments
$9,974K
Proceeds from sale of
property and equipment
$32K
Net cash (used in)
provided by investing...
$174,648K
Cash provided by
financing activities
$1,219K
Canceled cashflow
$699,631K
Net (decrease)
increase in cash and cash...
$72,110K
Canceled cashflow
$103,757K
Cash paid for
purchase of short-term...
$695,811K
Cash paid for
acquired intangible...
$3,500K
Cash paid for
purchase of property and...
$320K
Share-based compensation
expense
$44,388K
Amortization of intangible
assets
$3,110K
Prepaid expenses and
other current assets
-$2,481K
Accounts payable
$471K
Depreciation expense
$366K
Amortization of operating
right-of-use asset
$310K
Deferred revenue
$253K
Loss from sale of
property and equipment
-$71K
Net cash used in
operating activities
-$103,757K
Canceled cashflow
$51,450K
Net loss
-$107,322K
Accrued expenses and
other current...
-$16,010K
Accretion of discounts on
short-term investments,...
$15,738K
Accounts receivable, net
$12,859K
Inventory
$2,860K
Other long-term
liability
-$277K
Deposits and other
long-term assets
$109K
Operating lease liability
-$32K
Back
Back
Cash Flow
source: myfinsight.com
Day One Biopharmaceuticals, Inc. (DAWN)
Day One Biopharmaceuticals, Inc. (DAWN)